Skip to main navigation

About Us
- Leadership
- Board of Directors
Science
- Our Approach
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

About Us
- Leadership
- Board of Directors
Science
- Our Approach
- About CNM-Au8®
Pipeline
Patients
- EAP
Investors
Contact

News

Year

Clene submits new CNM-Au8 data to FDA ahead of upcoming meeting

ALS News Today

August 9, 2024

Golden Innovations: Nanocrystal Therapies for ALS and MS with Clene Nanomedicines’ Dr. Karen Ho

XTalks

July 17, 2024

Clene to submit new CNM-Au8 data to FDA ahead of meeting

ALS News Today

July 16, 2024

Accelerated Approval: ALS Drug Could Test New Congressional Directive On Survival

Pink Sheet - Citeline

July 12, 2024

New HEALEY-ALS Trial Results Show CNM-Au8’s Effect on Survival, Neurofilament Light

NeurologyLive

June 19, 2024

CNM-Au8 expanded access program for ALS is expanding in US

ALS News Today

June 4, 2024

Patient enrollment now complete in DNL343 arm of HEALEY ALS trial

ALS News Today

May 14, 2024

Multiple sclerosis patients find hope in ‘liquid gold'

Inquirer.Net

May 1, 2024

‘Liquid gold’ could bring new hope to multiple sclerosis patients, study suggests: ‘Profound benefit’

FOX News

April 30, 2024

Trials to watch: Four ALS drugs to keep an eye on

Yahoo Finance

April 30, 2024

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

1-801-676-9695
info@CleneNanomedicine.com
@CleneNano

Headquarters and Development

6550 South Millrock Drive, Suite G50
Salt Lake City, Utah 84121

Manufacturing, R&D

500 Principio Parkway West Suite 400
North East, Maryland 21901

Clene Nanomedicine, Inc. is a wholly owned subsidiary of Clene Inc. | © 2026 Clene Nanomedicine, Inc. - All rights reserved | PRIVACY POLICY | TERMS OF USE